(Q36470020)

14 August 2017

1 reference

title

Molecular targets and the treatment of myeloid leukemia (English)

1 reference

14 August 2017

5

Moore TB

1 reference

14 August 2017

Ikeda A

1

1 reference

14 August 2017

Shankar DB

2

1 reference

14 August 2017

Watanabe M

3

1 reference

14 August 2017

Tamanoi F

4

1 reference

14 August 2017

Sakamoto KM

6

1 reference

14 August 2017

5 May 2006

1 reference

Molecular Genetics and Metabolism

14 August 2017

1 reference

14 August 2017

88

1 reference

14 August 2017

3

1 reference

14 August 2017

216-224

1 reference

14 August 2017

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The multistep nature of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Are all cancer genes equal?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Genetics of myeloid leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Focus on myeloproliferative diseases and myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Targeted therapies in myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Acute promyelocytic leukemia: evolving therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

A PMLRARalpha transgene initiates murine acute promyelocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The AML1 and ETO genes in acute myeloid leukemia with a t(8;21).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Research on resistance to cancer drug Gleevec

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Overriding imatinib resistance with a novel ABL kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Targeted CML therapy: controlling drug resistance, seeking cure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Tyrosine kinases as targets for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Function and regulation of ras.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

BCL-2 family: regulators of cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Apoptosis-targeted therapies for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Cyclins and cyclin-dependent kinases: a biochemical view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The retinoblastoma gene (rb1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Cyclin E in human cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Deregulated cyclin E induces chromosome instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Cyclin-dependent kinases as new targets for the prevention and treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The AML1 Gene in the 8;21 and 3;21 Translocations in Chronic and Acute Myeloid Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Generation of the NUP98-HOXD13 fusion transcript by a rare translocation, t(2;11)(q31;p15), in a case of infant leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t(7;11)(p15;p15)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

TEL gene rearrangements in myeloid malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2006.03.011

10.1016/J.YMGME.2006.03.011

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference